Kidney Cancer, Version 3.2015

• DOI: 10.6004/jnccn.2015.0022
• Publication Date: 2017-04-14T16:06:35Z
• Authors: Robert J. Motzer; Eric Jonasch; Neeraj Agarwal; Clair Beard; Sam Bhayani; Graeme B. Bolger; Sam S. Chang; Toni K. Choueiri; Brian A. Costello; Ithaar H. Derweesh; Shilpa Gupta; Steven L. Hancock; Jenny J. Kim; Timothy M. Kuzel; Elaine T. Lam; Clayton Lau; Ellis G. Levine; Daniel W. Lin; M. Dror Michaelson; Thomas Olencki; Roberto Pili; Elizabeth R. Plimack; Edward N. Rampersaud; Bruce G. Redman; Charles J. Ryan; Joel Sheinfeld; Brian Shuch; Kanishka Sircar; Brad Somer; Richard B. Wilder; Mary Dwyer; Rashmi Kumar
• Keywords: Axitinib; Pazopanib; Kidney cancer; Cabozantinib

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations the clinical management of patients with clear cell and non-clear renal carcinoma. These Insights highlight recent updates/changes in these guidelines, updates include axitinib as first-line treatment option carcinoma, new data to support pazopanib subsequent therapy carcinoma after another tyrosine kinase inhibitor, guidelines follow-up